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Results demonstrate the importance of sensitivity analyses and thoughtful 
consideration of the metric and benchmark selection.  
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OBJECTIVES: Lupus nephritis (LN) is a severe complication of systemic lupus 
erythematosus (SLE). While LN has no designated ICD-9 code, various 
approaches have been used to identify patients in administrative data. The 
objective was to compare health resource utilization of LN patients using 
different algorithms in a single data source. METHODS: This study used the 
Impact Database, a commercial insurance claims database. SLE patients were 
identified using ICD-9 code 710.0 from ≥2 outpatient or 1 inpatient claims from 
01/2004 to 06/2011. SLE patients with LN were further identified under four 
different algorithms: (A) ≥1 renal diagnosis, (B) ≥2 renal diagnoses, (C) ≥3 renal 
diagnoses, and (D) ≥3 renal diagnoses plus ≥3 nephrologist visits. Health resource 
utilization and expenditure of outpatient/emergency department (ED) visits, 
hospitalizations, and prescriptions were examined for 12 months post index date 
of first renal diagnosis. RESULTS: A total of 93,957 patients were diagnosed with 
SLE. Among them, 24,357, 11,054, 8,895, and 6,307 cases had LN using algorithms 
A-D. LN cases identified by algorithms A-D had similar mean age (48.3, 46.7, 46.3, 
and 45.7 years) and gender distribution (85.2, 83.1, 82.7, and 81.8% females). LN 
patients from different algorithms also had similar annual frequency of 
outpatient visit (35.9, 41.0, 41.1, and 42.1), ED visit (1.4, 1.4, 1.4, and 1.5), 
hospitalization (0.8, 0.9, 0.9, and 0.9), and prescription (6.8, 7.3, 7.2, and 7.4). The 
annual medical expenditures were $33,176, $36,974, $36,241, and $38,883 for 
algorithms A, B, C, and D, respectively. CONCLUSIONS: Our results support that 
when studying health resource utilization, the results do not differ significantly 
based on the number of renal diagnoses codes. There is a difference in outcomes 
when requiring number of patients plus specialty subtype; however, in the case 
where specialty information is either unavailable or unreliable, using algorithms 
A-C proved equally reliable in an administrative claims database.  
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OBJECTIVES: Compare traditional and zero-inflated gamma regression models 
for the analysis of health care costs in an administrative claims database. 
Gamma regression models are widely used for the analysis of health care cost 
data and are appropriate for analyzing mean costs within patients incurring >$0. 
However, little research is available for the appropriateness of gamma regression 
on data with a high proportion of $0 costs. METHODS: This study used the 
HealthCore Integrated Research Environment to analyze hospitalization costs 
within 3,049 bipolar patients initiating antipsychotic medications (Drug X=2,398 
patients; Drug Y=651 patients). Results of a traditional gamma model and a zero-
inflated gamma model were compared. The zero-inflated model used SAS 
procedure NLMIXED to perform logistic regression modelling the probability of 
having a hospitalization, gamma regression modelling mean costs within 
patients having a hospitalization, and combining the two models to analyze 
differences in overall mean cost. RESULTS: There were 18.3% Drug X patients 
with an inpatient hospitalization, compared with 12.1% of Drug Y. Mean costs 
were higher for Drug X within only patients having an event ($17,721 vs. $11,425) 
and including patients with no event ($3,237 vs. $1,387). Gamma regression 
found the difference in the overall population to be significant (mean-
diff=$1,850, CI=[$1,463;$2,152], p<0.0001). The zero-inflated gamma regression 
model showed similar results (mean-diff=$1,850, CI=[$1,237;$2,464], p<0.0001). 
Consistent results between the models were also seen when adjusting for 
patient demographics, comorbidities, and prior medications: traditional gamma 
model (mean-diff=$2,173, CI=[$716;$1,297], p<0.0001), zero-inflated gamma 
model (mean-diff=$2,448, CI=[$597;$1,670], p<0.0001). CONCLUSIONS: When 
analyzing health care cost data containing >80% $0 costs, little difference was 
seen between traditional gamma regression and zero-inflated gamma regression 
models. The zero-inflated model uses complex coding, and requires advanced 
knowledge of statistical methods and SAS programming. Within data containing 
a large proportion of $0 costs, traditional gamma regression is appropriate for 
analyzing differences in mean costs.  
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OBJECTIVES: 1) To study the relative performance of various graphical and 
analytical diagnostics used to assess the assumption of an underlying gamma 
distribution for a commonly used model in the examination of health care 
expenditures (GLMAGALL – a generalized linear model assuming a gamma 
distribution with a log link relating the mean costs to a corresponding set of 
predictors), and 2) To investigate each diagnostic’s ability to discriminate 
between various assumed distributions (e.g., gamma versus log-normal) that 
may be potentially used in health care cost analysis. METHODS: Data sets will be 
created via Monte Carlo simulation of gamma (varying the shape and scale 
parameters) and other distributions, as well as, by altering the values for a small 
set of predictors. The results of the diagnostic study will be illustrated in a 
graphical and/or tabular format. RESULTS: Graphical diagnostics afford the 
analyst the ability to see subtle or dramatic departures from the model’s 
distributional assumptions that might not be as obvious by using an analytical 
model that provides a single summary statistic. CONCLUSIONS: The 
performance of a diagnostic procedure to assess the presence of a gamma 
distribution in a cost model or its ability to discriminate between one 
distribution and another is important; however, other factors must be 
considered before an analyst makes his or her final choice. The ease of executing 
the technique, its relative clarity of interpretation, and availability in a software 
package (without having to resort to extensive programming beyond what is 
provided by a standard statistical package) must all be considered to ensure that 
model adequacy testing may be performed readily so that the choice of a 
distribution for an expenditure model may be considered sound.  
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OBJECTIVES: To develop algorithms identifying if metastatic colorectal cancer 
(mCRC) patients were tested for KRAS (a tumor biomarker of EGFR-inhibitor 
response) using text documents (e.g., physician progress notes) within electronic 
medical records (EMR). METHODS: The sample consisted of 1,385 mCRC patients 
from the ACORN Data Warehouse. 300 patients were randomly selected for chart 
review and randomly assigned to training (n=150), validation (n=50), or testing 
datasets (n=100); 1,085 patients comprised a scoring dataset. Counts of terms in 
text-based content of patient EMRs were used to develop models predicting 
KRAS testing status. RESULTS: Several models were used to predict KRAS testing 
in the training sample. Decision tree (DT), random forest (RF), and adaptive 
boosting (AB) models performed best when applied to validation data not used in 
the earlier model development process. RF outperformed DT and AB. RF was the 
only model to produce a kappa ≥ 0.80 (within rounding) for both the validation 
and testing datasets. It also produced the highest kappa in the testing dataset 
(kappa=0.7994), as well as fewer false negatives. RF was used to score the 
remaining 1,085 patients. All patients predicted “tested” and a random sample of 
patients predicted “not tested” underwent chart review. The model correctly 
predicted KRAS “tested” 482/500 times (PPV=96.4%) and “not tested” 196/200 
times (NPV=98.0%), kappa= 0.970. CONCLUSIONS: Text mining yielded highly 
accurate classification of KRAS testing status among mCRC patients. Review of 
the small number of misclassified cases of KRAS testing identified ways to 
improve the model’s accuracy. These results may inform future research and 
reduce the need for labor-intensive and costly full chart review by human 
coders.  
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OBJECTIVES: To be able to identify observational studies of good enough quality 
for decision support by validating a set of screening questions to qualify studies 
likely to produce reasonably accurate and unbiased estimates of comparative 
effectiveness (CE). METHODS: An 11-item checklist was developed through 
literature review and consultation with experts from ISPOR, ISPE, payer groups, 
private sector and academia. Item content covers four quality domains: 
comparability of subjects, information about the exposure or intervention, 
outcome measurement, and statistical analysis, which are metrics similar to 
those used in assessing observational study quality for systematic reviews. 
Checklist items were tested using studies of drugs, medical devices and medical 
procedures. We focused on research quality, not applicability to any decision. A 
fundamental challenge was to find a gold standard against which to test 
checklist items. 113 volunteers from 5 continents each rated >3 articles (N=280 
assessments) from three validation sets of studies that 1) had quality 
assessments published in systematic reviews; 2) were assessed for quality by one 
of nine advisors from academic and payer groups; or 3) were assessed for quality 
by two of the nine advisors. RESULTS: Expert reviews uncovered an unsettling 
lack of agreement about what “good” looks like, especially in situations that 
lacked context, with 52% concordance (5 experts, 23 assessments.) The single 
best performing checklist item, data quality for the primary outcome(s), scored 
>= 0.67 for positive predictive value in 4 of 6 samples and > = 0.67 for negative 
predictive values in all 6 samples. Another high scoring question, sensitivity 
analyses, had a positive predictive value >= 0.69 for in all 6 samples. 
CONCLUSIONS: This quantitative study shows that many content items 
recommended by experts do not consistently distinguish high quality 
observational CE studies.  
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